Biogen, Celgene, Pharmacyclics, Hayman Capital Management autoimmune, cancer news
Hedge fund manager Kyle Bass filed additional inter partes reviews (IPRs) in the U.S. Patent and Trademark Office challenging patents covering Celgene’s Revlimid lenalidomide, Pharmacyclics’ Imbruvica ibrutinib and Biogen’s Tecfidera dimethyl fumarate.
An entity associated with hedge fund Hayman Capital filed an IPR challenging U.S. Patent No. 6,045,501, which was issued in 2000 and covers methods for preventing fetal exposure to tetragenic drugs, including Revlimid. The IPR argues Celgene’s claims are obvious, noting initial rejections by the PTO on those grounds. The ‘501 patent is set to expire in 2018. There are 24 Orange Book-listed patents covering Revlimid, with the last expiring in 2028. U.S. sales of Revlimid were $797 million in 4Q14. Celgene markets the thalidomide analog to treat mantle cell lymphoma (MCL), multiple myeloma (MM) and myelodysplastic syndromes (MDS). The company reported $5 billion in 2014 worldwide sales of Revlimid. ...